BOARD OF DIRECTORS

The Board consists of nine Directors, including four executive Directors, two non-executive Directors and three independent non-executive Directors. The following table sets forth certain information regarding the Directors.

Name	Age	Date of joining the Group	Date of appointment as a Director	Position	Responsibilities	Relationship with other Directors and senior management
Mr. CHEN Changqing (陳長清)	63	January 2018	August 2019	Executive Director and Chairman of the Board	Overall strategic planning, resource integration and enterprise management of our Group	Nil
Mr. LUO Qi (駱旗)	55	October 2018	August 2019	Executive Director and general manager	Overall operations, procurement, human resources and administrative management of the Group	Nil
Mr. WANG Dong (王東)	53	August 2020	December 2020	Executive Director and executive general manager	Supply chain management and management of the subsidiaries of the Group	Nil
Mr. ZHANG Baozeng (張寶增)	44	May 2019	January 2022	Executive Director, chief financial officer, board secretary and joint company secretary	Overall financial operations and investor relations of our Group and ensuring compliance with governance requirements	Nil
Ms. CHEN Qiao (陳巧)	46	May 2021	May 2021	Non-executive Director	Providing strategic guidance and independent oversight to our Board	Nil
Ms. WU Xiaoyi (吳小儀)	31	February 2022	September 2025	Non-executive Director	As employee representative Director	Nil
Dr. YU Yumiao (余玉苗)	61	July 2022	July 2022	Independent non-executive Director	Providing independent judgment to our Board	Nil
Mr. ZHANG Xiaolu (張曉路)	59	July 2022	July 2022	Independent non-executive Director	Providing independent judgment to our Board	Nil
Mr. ZHANG Ping (張平)	61	September 2025	September 2025	Independent non-executive Director	Providing independent judgment to our Board	Nil

Executive Directors

Mr. CHEN Changqing (陳長清), aged 63, is the Chairman of the Board and our executive Director, and is primarily responsible for overall strategic planning, resource integration and enterprise management of our Group. Mr. Chen joined our Group in January 2018, was appointed as the Chairman of the Board and our Director since August 2019, and was re-designated as an executive Director in September 2025. He is also a director of Hong Kong Rongtai Health Company Limited (香港融泰健康有限公司) and HK Tailai Information Technology Limited (香港泰萊信息科技有限公司). Hong Kong Rongtai Health Company Limited and HK Tailai Information Technology Limited are members of our Group.

Mr. Chen is a leader in the pharmaceutical industry, with more than 20 years of industry experience. From February 2006 to May 2010, Mr. Chen served as a deputy general manager of China National Medicines Group Corporation* (中國藥材集團公司), the predecessor of China Traditional Chinese Medicine Co., Ltd.* (中國中藥有限公司), and was primarily responsible for its business expansion and management. From May 2010 to May 2015, Mr. Chen served as the general manager of Sinopharm, a company whose shares are listed on the Shanghai Stock Exchange (stock code: 600511), and was primarily responsible for its business and strategic management, senior operations and marketing. From July 2015 to August 2016, Mr. Chen served as the vice president of Shenzhen Kangzhe Pharmaceutical Co., Ltd.* (深圳康哲藥業控股公司) ("**Shenzhen Kangzhe**"), a wholly-owned subsidiary of CMS, and was primarily responsible for its business and strategic management, market development and business innovation. From January 2017 to December 2018, Mr. Chen served as the president of Beijing Rongguang Electronic Commerce Co., Ltd.* (北京融貫電子商務有限公司), an internet company specialising in integrated services across the pharmaceutical industry, and was primarily responsible for its business and strategic management.

Mr. Chen received his EMBA degree from Sun Yat-Sen University (中山大學) in December 2005. He received his bachelor's degree in Chinese Masteria Medica from Guangzhou University of Chinese Medicine (廣州中醫藥大學) in July 1991.

Mr. LUO Qi (駱旗), aged 55, is our executive Director and general manager, and is primarily responsible for overall operations, procurement, human resources and administrative management of the Group. Mr. Luo joined our Group in October 2018, was appointed as our Director since August 2019, and was re-designated as an executive Director in September 2025.

Mr. Luo has more than 30 years of working and management experience in pharmaceutical sales and marketing. From August 1992 to August 1998, Mr. Luo worked at Xi'an Shuanghe Pharmaceutical Co., Ltd.* (西安雙鶴醫藥股份有限公司), the predecessor of Xi'an Pharmaceutical Co., Ltd.* (西安醫藥股份有限公司), and from July 1998 to July 2012, he served as a regional business manager of commercial department of Shanghai Roche Pharmaceuticals Ltd.* (上海羅氏製藥有限公司), and was primarily responsible for building a regional market response mechanism, promoting the coordinated development of "academic + business"; establishing and cultivating teams, and improving the construction of talent echelons. From August 2012 and September 2015, Mr. Luo served as the director of distribution division of Sinopharm, and was primarily responsible for coordinating the upgrade of the group's business system, building a hierarchical authorization and supplier collaboration mechanism, and improving supply chain efficiency; leading the construction of retail direct supply channels and teams and promoting the implementation of digital systems. From November 2015 to February 2017, Mr. Luo served as the director of the commercial and retail development department of Shenzhen

Kangzhe, and was primarily responsible for formulating a national retail channel strategy, establishing a channel and business team, and promoting the increase of product market share in the chain system; building a standardized operation and service system to promote the implementation of business regulations.

Mr. Luo received his bachelor's degree in national manager management from Northwest University (西北大學) in July 1992.

Mr. WANG Dong (王東), aged 53, is our executive Director and executive general manager, and is primarily responsible for supply chain management and management of the subsidiaries of the Group. Mr. Wang joined our Group in August 2020, was appointed as our Director since December 2020, and was re-designated as an executive Director in September 2025.

Mr. Wang has more than 30 years of working and management experience in the pharmaceutical supply chain management. From April 1996 and May 2011, Mr. Wang has served as a commercial director of Shanghai Roche Pharmaceuticals Ltd.* (上海羅氏製藥有限公司), and was primarily responsible for distributorship and business development. From June 2012 to November 2013, he served as a procurement director of Sinopharm. From November 2013 to November 2019, Mr. Wang worked at Roche Diagnostics (Shanghai) Ltd.* (羅氏診斷(產品)上海公司) with his last position being the director of regional channel management operation. From November 2019 and April 2020, he served as a sales operation director of Siemens Healthineers Ltd..

Mr. Wang received his bachelor's degree in clinical medicine from Shandong Medical University (山東醫科大學) in July 1995.

Mr. ZHANG Baozeng (張寶增), aged 44, is our executive Director, chief financial officer, board secretary and joint company secretary, and is primarily responsible for overall financial operations and investor relations of our Group and ensuring compliance with governance requirements. Mr. Zhang joined our Group in May 2019, was appointed as our Director since January 2022, and was re-designated as an executive Director in September 2025.

Mr. Zhang has more than 10 years of working and management experience in financial operations. From July 2015 to October 2017, Mr. Zhang served as a senior manager of Yaopharma Co., Ltd.* (重慶藥友製藥有限責任公司), and was primarily responsible for financial operations. From November 2017 to April 2019, he served as the head of the financial shared service center of Hemony Pharmaceutical Co., Ltd.* (海默尼藥業股份有限公司), and was primarily responsible for financial operations of the whole group.

Mr. Zhang received his bachelor's degree in economics from Southwestern University of Finance and Economics (西南財經大學) in June 2005.

Mr. Zhang has been a PRC certified management accountant since October 2020, and a PRC certified senior accountant since March 2021.

Non-executive Directors

Ms. CHEN Qiao (陳巧), aged 46, is our non-executive Director nominated by Guangzhou Zhengda, Lishui Tongda, Hangzhou Huipu and Horgos Dadao, and is primarily responsible for providing strategic guidance and independent oversight to our Board. Ms. Chen joined our Group in May 2021, was appointed as our Director since May 2021, and was re-designated as a non-executive Director in September 2025.

Ms. Chen served as a managing director of Tianjin Hidea Venture Capital Management Co., Ltd.* (天津海達創業投資管理有限公司) since February 2011, focusing on investments in the healthcare industry. She served as an investment manager of Tianjin TEDA Venture Capital Corporation Co., Ltd.* (天津泰達科技投資股份有限公司) from July 2006 to January 2011, and was primarily responsible for project sourcing and investment.

Ms. Chen is a director in following companies:

- Huayitaikang Pharmaceutical Co., Ltd.* (華益泰康藥業股份有限公司);
- Beijing Sun-Novo Pharmaceutical Research Co., Ltd.* (北京陽光諾和藥物研究股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 688621);
- Guangzhou Henovcom Bioscience Co., Ltd.* (廣州市恒諾康醫藥科技有限公司); and
- Lexenpharm (Suzhou) Limited* (立生醫藥(蘇州)有限公司).

Ms. Chen has been pursuing her EMBA degree at Cheung Kong Graduate School of Business (長江商學院) since March 2024. She received her FMBA degree from Tsinghua University (清華大學) and The Chinese University of Hong Kong (香港中文大學) in November 2017. She received her master's degree in pharmacy from China Pharmaceutical University (中國藥科大學) in June 2006, and her bachelor's degree in pharmaceutical preparations from China Pharmaceutical University (中國藥科大學) in July 2003, respectively.

Ms. Chen obtained a Qualification for Practicing in China's Securities Investment Fund Industry (中國證券投資基金業從業資格) in July 2017 from the Asset Management Association of China (中國證券投資基金業協會). She was awarded as one of the Top 20 Chinese Healthcare Investors in 2020–2021 (2020–2021年度中國醫療健康投資人物TOP20), the Best Young Investor in China's Equity Investment Industry in 2021 (2021年度中國股權投資行業最佳青年投資人), the Most Popular Young Investor in 2021 (2021年度最具人氣青年投資人), the Best Investor in China's Healthcare Industry in 2021–2022 (2021–2022年度中國醫療健康最佳投資人物), and the Best Investor in China's Healthcare Sector in 2022–2023 (2022–2023年度中國醫療健康領域最佳投資人物) by Chinese Venture (融資中國) in July 2021, May 2022, May 2022, August 2022 and July 2023, respectively. She also won awards of Top 100 Chinese Venture Capitalists of 2021 (2021年度中國最佳創業投資人TOP100) and Top 50 Supernova Investors of 2022 (2022年度超新星投資人TOP50) from China Venture Investment Consulting, Ltd. (投中信息) in August 2022 and May 2023, respectively. Additionally, Ms. Chen was also awarded as the Young Healthcare Investor of the Year (年度醫療健康青年投資家) by Haoyue Capital (浩悦資本) in April 2022, April 2023 and April 2024, respectively. She received an honor as one of the Top 50 Most Influential Investors of 2023 (2023年度最具影響力投資人TOP50) from CHC Medical Consulting (CHC醫療諮詢) in May 2024.

Ms. WU Xiaoyi (吳小儀), aged 31, is our non-executive Director, and is an employee representative director (職工代表董事). Ms. Wu joined our Group in February 2022. She has been an assistant to the Chairman of the Board since February 2022 and was appointed as a non-executive Director in September 2025.

Ms. Wu served as a content operations specialist of Yatsen Global, a company listed on the New York Stock Exchange (stock code: YSG), from July 2018 to October 2018. She was then served as an e-commerce operations specialist in Guangzhou Lalami Information Technology Co., Ltd.* (廣州市拉拉米信息科技股份有限公司) from November 2018 to March 2020 and was primarily responsible for managing brand store operations on platforms. From April 2020 to January 2022, Ms. Wu served as an assistant director in Guangzhou Huiran Information Technology Co., Ltd.* (廣州匯然信息科技有限公司) and was primarily responsible for supporting the director in sales business development and customer relationship management.

Ms. Wu received her bachelor's degree in public health, majoring in Health Inspection and Quarantine from Guangdong Pharmaceutical University (廣東藥科大學) in June 2018.

Independent Non-executive Directors

Dr. YU Yumiao (余玉苗), aged 61, is our independent non-executive Director, and is primarily responsible for providing independent judgment to our Board. Dr. Yu joined our Group in July 2022, was appointed as our Director since July 2022, and was re-designated as an independent non-executive Director in September 2025.

Dr. Yu has more than 35 years of experience in teaching and researching accounting and auditing. She served as the teaching assistant and lecturer of audit department in School of Economics of Wuhan University (武漢大學) from July 1989 to September 1996. She then served as an associate professor of department of accounting in School of Economics and Management of Wuhan University (武漢大學) from October 1996 to October 2001. She has been serving as a professor and doctoral supervisor of department of accounting in School of Economics and Management of Wuhan University (武漢大學) since September 2002. During her tenure of Wuhan University (武漢大學), she has been primarily responsible for teaching and research of accounting and auditing.

Dr. Yu served as an independent director of Linktel Technologies Co., Ltd.* (武漢聯特科技股份有限公司) from September 2020 to April 2026, a company whose shares are listed on the Shenzhen Stock Exchange (stock code: 301205). Dr. Yu has also been serving as an independent director of Humanwell Healthcare (Group) Co., Ltd. (人福醫藥集團股份公司) since July 2025, a company whose shares are listed on the Shanghai Stock Exchange (stock code: 600079), and as an independent director of Wuhan Healthgen Biotechnology Corp.* (武漢禾元生物科技股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 688765), since July 2022, respectively.

Dr. Yu received his doctorate degree in economics from Wuhan University (武漢大學) in December 1997. He received her master's degree in economics from Wuhan University (武漢大學) in October 1989, and his bachelor's degree in business administration from Wuhan University (武漢大學) in July 1986, respectively.

Mr. ZHANG Xiaolu (張曉路), aged 59, is our independent non-executive Director, and is primarily responsible for providing independent judgment to our Board. Mr. Zhang joined our Group in July 2022, was appointed as our Director since July 2022, and was re-designated as an independent non-executive Director in September 2025.

Mr. Zhang has been serving as the managing partner of Hubei Dingli Zhongbang Law Firm (湖北鼎力眾邦律師事務所) from June 2004 to June 2018 and has been serving as a specialist lawyer at the same firm since June 2018.

Mr. Zhang received his master's degree in law from Zhongnan University of Economics and Law (中南財經政法大學) in June 2001, and his bachelor's degree in laws from the Law School of Zhongnan University of Economics and Law in June 1989, respectively.

Mr. Zhang Ping (張平), aged 61, is our independent non-executive Director, and is primarily responsible for providing independent judgment to our Board. Mr. Zhang was appointed as an independent non-executive Director in September 2025.

Mr. Zhang has at least 15 years of experience in the pharmaceutical industry. He served as the general manager of Sinopharm Group Anhui Co., Ltd.* (國藥控股安徽有限公司) from March 2009 to May 2022, where he was primarily responsible for managing company decisions and operations. He later served as the deputy general manager of Sinopharm Group Distribution Co., Ltd.* (國藥控股分銷中心有限公司) from May 2019 to December 2023, where he was primarily responsible for channel sales.

Mr. Zhang was awarded the Anhui Labor Day Medal (安徽省五一勞動獎章) in June 2020.

Mr. Zhang received his master's degree in business administration from Nankai University (南開大學) in June 2013. He received his bachelor's degree in operations from the Party School of Anhui Provincial Committee of C.P.C* (中共安徽省委黨校) in July 1999.

SENIOR MANAGEMENT

Our senior management is responsible for the day-to-day management of our business. The following table sets forth the key information about our senior management as of the Latest Practicable Date.

Name	Age	Date of joining the Group	Date of appointment as a senior management	Position	Responsibilities	Relationship with other Directors and senior management
Mr. LUO Qi (駱旗)	55	October 2018	October 2018	Executive Director and general manager	Overall operations, procurement, human resources and administrative management of the Group	Nil
Mr. WANG Dong (王東)	53	August 2020	August 2020	Executive Director and executive general manager	Supply chain management and management of the subsidiaries of the Group	Nil

Name	Age	Date of joining the Group	Date of appointment as a senior management	Position	Responsibilities	Relationship with other Directors and senior management
Mr. ZHANG Baozeng (張寶增)	44	May 2019	May 2022	Executive Director, chief financial officer, board secretary and joint company secretary	Overall financial operations and investor relations of our Group and ensuring compliance with governance requirements	Nil
Mr. ZHANG Weizheng (張衛征)	42	March 2019	March 2022	Deputy general manager	Procurement of pharmaceuticals and operational management of the subsidiaries of our Group	Nil
Mr. CHENG Huaping (程華平)	53	June 2018	June 2018	Deputy general manager	Managing the retail division and operational management of the subsidiaries of our Group	Nil

Mr. LUO Qi (駱旗), aged 55, is our executive Director and general manager.

Mr. WANG Dong (王東), aged 53, is our executive Director and executive general manager.

Mr. ZHANG Baozeng (張寶增), aged 44, is our executive Director, chief financial officer, board secretary and joint company secretary.

See "—Executive Directors" above for details of biography for each of Mr. Luo Qi, Mr. Wang Dong and Mr. Zhang Baozeng.

Mr. ZHANG Weizheng (張衛征), aged 42, is our deputy general manager, and is primarily responsible for procurement of pharmaceuticals and operational management of the subsidiaries of our Group.

Mr. Zhang has more than 15 years of experience in sales and marketing of pharmaceuticals. He joined our Group in March 2019, has been serving as our deputy general manager since March 2022, and the general manager of Rongtai Pharmaceutical (Anhui) Co., Ltd. (融泰醫藥(安徽)有限公司) since December 2024, respectively. From September 2007 to May 2010, Mr. Zhang served as the sales manager of Sinopharm Holding Guangdong Dongfang New Speciality Medicine Co., Ltd.* (國藥控股廣東東方新特藥有限公司). From April 2013 to April 2014, Mr. Zhang served as the sales manager of AstraZeneca (Wuxi) Trading Co., Ltd.* (阿斯利康(無錫)貿易有限公司). From September 2014 to March 2019, he served as the procurement manager of Pharmacy Technology (Shanghai) Co., Ltd.* (壹藥網科技(上海)股份有限公司), and was primarily responsible for procurement.

Mr. Zhang received his bachelor's degree in pharmacy from Zhengzhou University (鄭州大學) in June 2007.

Mr. CHENG Huaping (程華平), aged 53, is our deputy general manager, and is primarily responsible for managing the retail division and operational management of the subsidiaries of our Group.

Mr. Cheng has more than 20 years of experience in sales and marketing of pharmaceuticals. He joined our Group in June 2018, has been serving as our deputy general manager since June 2018, and the chairman of the board of directors of Rong Tai Lanzhou since January 2025, respectively. From September 2003 to November 2015, he served as the director of retail division of Sinopharm. From November 2015 to November 2016, Mr. Cheng served as the director of retail division of Shenzhen Kangzhe. From December 2016 to May 2018, Mr. Cheng served as a deputy general manager of Hunan Ruihua Pharmaceutical Trading Co., Ltd.* (湖南瑞華醫藥經營有限公司).

Mr. Cheng received his bachelor's degree in fermentation engineering from Hubei University of Technology (湖北工業大學) in July 1997. He obtained his college degree in pharmacy in Shanghai Jiao Tong University (上海交通大學) in January 2017 by remote learning.

JOINT COMPANY SECRETARIES

Mr. ZHANG Baozeng (張寶增), aged 44, is our executive Director, chief financial officer, board secretary and joint company secretary and is primarily responsible for overseeing the financial operations and investor relations of our Group. See "—Executive Directors" above for details of biography for Mr. Zhang Baozeng.

Mr. WONG Chun Wing Samuel (黃俊穎) has been appointed as one of our joint company secretaries with effect from **[REDACTED]**.

Mr. Wong serves as an assistant manager of the Listing Services Department of TMF Hong Kong Limited and is responsible for provision of corporate secretarial and compliance services to listed company clients. He has over eight years of experience in the company secretarial field. Mr. Wong is an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute (formerly known as The Institute of Chartered Secretaries and Administrators) in the United Kingdom. Mr. Wong is also serving as one of the joint company secretaries in the following companies listed on the Stock Exchange: CMON Limited (stock code: 1792), Qunabox Group Limited (stock code: 917), Shandong Gold Mining Co. Ltd. (stock code: 1787) (Shandong Gold Mining Co. Ltd is also listed on the Shanghai Stock Exchange (stock code: 600547)) and Zhejiang Galaxis Technology Group Co., Ltd. (stock code: 2729).

Mr. Wong received his bachelor's degree of business administration from the Hang Seng University of Hong Kong (formerly known as Hang Seng Management College) in November 2017.

FURTHER INFORMATION ABOUT OUR DIRECTORS AND SENIOR MANAGEMENT

On July 15, 2014, the SSE issued a letter of regulatory concern to Mr. Chen, a then director and general manager of Sinopharm, in relation to the acquisition of 10,700 shares (the "**Relevant Shares**") of Sinopharm by Mr. Chen on February 25, 2014 (the "**Incident**"). The acquisition took place during the 30-day blackout period immediately preceding the intended publication date of Sinopharm's 2013 annual report on March 20, 2014, and was therefore in breach of Articles 3.1.4 and 3.1.6 of the then-effective SSE Listing Rules (2013 Revision), as well as Article 13 of the Rules on the Management of Shares Held by Directors, Supervisors, and Senior Management of Listed Companies and Their Changes.

At the time, Mr. Chen had delegated the operation of his personal securities account to his elder brother, Mr. Chen Changhong ("**Mr. CH Chen**") due to his demanding professional commitments, and had specifically instructed Mr. CH Chen not to deal in securities of Sinopharm. According to Mr. CH Chen, the acquisition was made based on market observations and he had inadvertently disregarded Mr. Chen's instructions. Upon becoming aware of the Incident, Mr. Chen immediately resumed control of his securities account and reported the matter to Sinopharm, which voluntarily reported the Incident to the SSE. Mr. Chen did not dispose of the Relevant Shares immediately to avoid breaching short-term trading restrictions, and voluntarily disposed of the shares in December 2014 to rectify the non-compliance.

As at the Latest Practicable Date and to our best knowledge, (i) the incident have been concluded, (ii) there has not been any further regulatory request to, action against or correspondence with Mr. Chen from or by the SSE, and (iii) other than disclosed above, Mr. Chen has not been imposed any other penalties or involved in any other investigation, hearing or proceeding brought or instituted by any securities regulatory authority or stock exchange, relating to the Incident.

Notwithstanding the Incident, our Board is of the view that such letter of regulatory concern from the SSE does not impugn the integrity or suitability of Mr. Chen to serve as our Director under Rules 3.08 and 3.09 of the Listing Rules, based on the following factors:

- such incident took place before the Track Record Period and Mr. Chen has not experienced any similar incident since the commencement of the Track Record Period and as of the Latest Practicable Date;

- the non-compliant conduct involved in the Incident was unintentional and primarily due to inadvertent oversight, and did not involve findings of fraud and dishonesty on the part of Mr. Chen or raise concern on his integrity; and once being aware of the non-compliant conducts, Mr. Chen took rectification measures as appropriate, including attending training sessions and making the relevant disclosure;

- as advised by our PRC Legal Advisor, the letter of regulatory concern from the SSE did not constitute any administrative penalty or disciplinary sanction under the PRC securities regulatory laws, regulations or rules;

- the Group's internal controls are adequate and effective in preventing the occurrence of similar incidents. Specifically, the Company has adopted the Insider Trading Prevention Policy to prevent insider dealing and ensure compliance with applicable laws and regulations. In accordance with its Insider Trading Prevention Policy, the Company prohibits any director or employee from dealing in the Company's securities while in possession of unpublished price-sensitive information or during designated blackout periods, which generally cover 60 days prior to the publication of annual results and 30 days prior to interim or quarterly results. A pre-clearance mechanism is in place for exceptional circumstances, requiring written notification and approval before any trade can be executed.

The Company also maintains a record of all notifications and confirmations and requires post-trade reporting to update interest records. These restrictions extend to close associates of the employees and apply to securities held by the employees through trusts or managed funds;

- the Company will adopt (a) the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules; and (b) written guidelines no less exacting than the Model Code for relevant employees of the Company for their dealings in the Company's securities, as part of its securities trading rules and procedures upon **[REDACTED]**; and

- in anticipation of the **[REDACTED]**, we have engaged an internal control consultant to review the effectiveness of our internal controls associated with our business processes, including controls on directors' and senior management's dealings in the Company's securities and disclosure of information, and no internal control deficiency was found based on the work performed in relation to the sufficiency and effectiveness of the enhanced internal control measures.

BOARD COMMITTEES

Audit Committee

Our Company has established an Audit Committee (with effect from the **[REDACTED]**) with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code as set out in Appendix C1 to the Listing Rules. The Audit Committee consists of three members, namely Dr. Yu Yumiao, Mr. Zhang Xiaolu, Ms. Chen Qiao. Dr. Yu has been appointed as the chairman of the Audit Committee. The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal control system of our Group, oversee the audit process, review and oversee the existing and potential risks of our Group, and perform other duties and responsibilities as assigned by our Board.

Remuneration Committee

Our Company has established a Remuneration Committee (with effect from the **[REDACTED]**) with written terms of reference in compliance with Rule 3.25 of the Listing Rules and the Corporate Governance Code as set out in Appendix C1 to the Listing Rules. The Remuneration Committee has three members, namely Dr. Yu Yumiao, Mr. Zhang Baozeng, and Mr. Zhang Ping. Mr. Zhang Ping has been appointed as the chairman of the Remuneration Committee. The primary duties of the Remuneration Committee are to establish and review the policy and structure of the remuneration for our Directors and senior management and make recommendations on employee benefit arrangements.

Nomination Committee

Our Company has established a Nomination Committee (with effect from the **[REDACTED]**) with written terms of reference in compliance with the Corporate Governance Code as set out in Appendix C1 to the Listing Rules. The Nomination Committee consists of three members, namely Mr. Chen Changqing, Mr. Zhang Ping, and Mr. Zhang Xiaolu. Mr. Chen is the chairman of the Nomination Committee. The primary duties of the Nomination Committee are to make recommendations to our Board on the appointment and removal of Directors of our Company.

CORPORATE GOVERNANCE CODE

Our Company is committed to achieving high standards of corporate governance with a view to safeguarding the interests of our Shareholders. To accomplish this, our Company intends to comply with Corporate Governance Code set out in Appendix C1 to the Listing Rules and the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules after the **[REDACTED]**.

Our Directors have a balanced mix of knowledge and skills, including but not limited to overall business management, finance, legal, accounting, and marketing. They obtained degrees in diversified majors including management, economics, medicine and pharmacy. The Board is of the view that our Board satisfies the Board Diversity Policy. Two of our Directors are female. While we recognize that the gender diversity at our Board level can be improved given the majority of our Directors are male, we will continue to apply the appointment criteria based on competence and with reference to the overall diversity policy. Our Board will also ensure that an appropriate balance of gender diversity is achieved with reference to investors' expectations, and international and local recommended best practices.

To further ensure gender diversity on our Board in the long run, our Group will also identify and select several female individuals with a diverse range of skills, experience, and knowledge in different fields from time to time, and maintain a list of such female individuals who possess qualities to become our Board members, which will be reviewed by our Nomination Committee periodically in order to develop a pipeline of potential successors to our Board to promote gender diversity of our Board. In addition to the Board level, we are also committed to promoting gender diversity at the senior management and all other levels of our Group by providing career development opportunities for female staff, making available to them knowledge and skills training in support of succession planning and ensuring future gender diversity can be achieved on the Board.

The Nomination Committee is responsible for reviewing the diversity of the Board. After **[REDACTED]**, the Nomination Committee will monitor and evaluate the implementation of the Board Diversity Policy from time to time to ensure its continued effectiveness. The Nomination Committee will also include in successive annual reports a summary of the Board Diversity Policy, including any measurable objectives set for implementing the Board Diversity Policy and the progress on achieving these objectives.

CONFIRMATION FROM OUR DIRECTORS

Rule 8.10 of the Listing Rules

None of our Directors had interests in any other companies as of the Latest Practicable Date that may, directly or indirectly, compete with our business and would require disclosure under Rule 8.10 of the Listing Rules.

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules on September 5, 2025, and (ii) understands his or her obligations as a director of a listed company under the Listing Rules.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors confirms (i) his/her independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules, (ii) that he/she had no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company under the Listing Rules as of the Latest Practicable Date, and (iii) that there are no other factors that may affect his/her independence at the time of his/her appointment.

Interests of Directors and members of senior management

Except as disclosed in this Document, as of the Latest Practicable Date, each of the Directors and members of senior management (i) did not hold other positions in our Group as of the Latest Practicable Date; (ii) had no other relationship with any of the Directors and members of senior management as of the Latest Practicable Date; (iii) did not hold any other directorship and supervisor's position in listed companies in the three years prior to the Latest Practicable Date. To the best of the knowledge, information and belief of our Directors and senior management, having made all reasonable enquiries, there was no other matter with respect to the appointment of our Directors and senior management that needs to be brought to the attention of our Shareholders and there was no information relating to our Directors and senior management that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules. For the Directors' interests in the Shares within the meaning of Part XV of the SFO, see "Appendix IV—Statutory and General Information."

REMUNERATION OF DIRECTORS

The compensation and remuneration of the Directors and members of the senior management of the Company are determined by the Shareholders' meetings and the Board as appropriate in the form of salaries and bonuses. The Company also reimburses them for expenses that are necessary and reasonably incurred in providing services to the Company or discharging their duties in relation to the operations of the Company. When reviewing and determining the specific remuneration packages for our Directors and members of the senior management of the Company, the Shareholders' meetings, and the Board take into account factors such as salaries paid by comparable companies, time commitment, level of responsibilities, employment elsewhere in our Group and desirability of performance-based remuneration.

Our Company offers executive Directors and members of senior management, who are also employees, compensation in the form of salaries, bonuses, social security plans, housing provident fund plans, and other benefits. The independent non-executive Directors receive compensation based on their responsibilities.

The aggregate amounts of remuneration paid to the Directors for the three years ended December 31, 2025, were approximately RMB2,270,000, RMB2,748,000 and RMB2,737,000, respectively.

The aggregate amounts of remuneration paid to the five highest-paid individuals for the three years ended December 31, 2025 were approximately RMB2,752,000, RMB3,237,000 and RMB3,081,000, respectively.

No remuneration was paid by the Company to the Directors or the five highest paid individuals as an inducement to join or upon joining the Company or as compensation for loss of office during the Track Record Period. Furthermore, none of the Directors had waived or agreed to waive any remuneration during the Track Record Period.

COMPLIANCE ADVISOR

The Company appointed Altus Capital Limited as the compliance advisor pursuant to Rule 3A.19 of the Listing Rules. Our Compliance Advisor will provide us with guidance and advice as to compliance with the Listing Rules and applicable Hong Kong laws. Pursuant to Rule 3A.23 of the Listing Rules, our compliance advisor will advise our Company in the following circumstances:

- before the publication of any regulatory announcement, circular, or financial report;
- where a transaction, which might be notifiable or connected, is contemplated, including share issues and share repurchases;
- where our Company proposes to use the **[REDACTED]** of the **[REDACTED]** in a manner that is different from that detailed in this Document or where our business activities, developments, or results deviate from any forecasts, estimates, or other information in this Document; and
- where the Stock Exchange makes an inquiry of our Company regarding unusual movements in the price or trading volume of the Shares, the possible development of a false market in the Shares, or any other matters.

The terms of the appointment of the compliance advisor will commence on the **[REDACTED]** and end on the date when the Company distributes the annual report of its financial results for the first full financial year commencing after the **[REDACTED]**.